Triodos Investment Management BV Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Triodos Investment Management BV grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 42,000 shares of the medical equipment provider’s stock after buying an additional 6,750 shares during the period. Triodos Investment Management BV’s holdings in Hologic were worth $3,028,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. General Partner Inc. acquired a new stake in Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment increased its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $62.32 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 19.66, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The business has a 50 day simple moving average of $65.41 and a 200-day simple moving average of $73.50.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HOLX shares. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.